In an exclusive TODAY interview, Drake Bell addresses criticism that while he has spoken out about his own past and tried to help other children avoid abuse, he also pleaded guilty to crimes involving a teenage girl.
Utility Therapeutics Ltd.: UTILITY Therapeutics Announces Scientific Advisory Board
SAB includes key opinion leaders for infectious diseases and urinary tract infections
LONDON, UK / ACCESSWIRE / May 11, 2021 / UTILITY therapeutics Ltd., a biotechnology company focused on the U.S. development and commercialization of two European-approved antibiotics for the treatment of urinary tract infections (UTI), announced today that it has established a Scientific Advisory Board (SAB) that will be chaired by Keith A. Rodvold, PharmD and Distinguished Professor
of Pharmacy at the College of Medicine at the University of Illinois in Chicago. We are honored to have such a prestigious and experienced group of medical and industry experts join our Scientific Advisory Board, stated Tom Hadley, President and Chief Commercial Officer of UTILITY therapeutics. Their guidance will be extremely valuable as we advance our two product candidates for the treatment of UTIs. We look forward to working
UTILITY Therapeutics Announces Scientific Advisory Board
ACCESSWIRE
SAB includes key opinion leaders for infectious diseases and urinary tract infections
LONDON, UK / ACCESSWIRE / May 11, 2021 / UTILITY therapeutics Ltd., a biotechnology company focused on the U.S. development and commercialization of two European-approved antibiotics for the treatment of urinary tract infections (UTI), announced today that it has established a Scientific Advisory Board (SAB) that will be chaired by Keith A. Rodvold, PharmD and Distinguished Professor
of Pharmacy at the College of Medicine at the University of Illinois in Chicago. We are honored to have such a prestigious and experienced group of medical and industry experts join our Scientific Advisory Board, stated Tom Hadley, President and Chief Commercial Officer of UTILITY therapeutics. Their guidance will be extremely valuable as we advance our two product candidates for the treatment of UTIs. We look forward to working with our SAB to